Atlas FDA

DEXCOM G5 Mobile Continuous Glucose Monitoring System

FDA premarket approval P120005/S090 · decided 2023-01-12

Approval details

PMA number
P120005
Supplement
S090
Supplement type
Normal 180 Day Track No User Fee
Supplement reason
Postapproval Study Protocol
Trade name
DEXCOM G5 Mobile Continuous Glucose Monitoring System
Generic name
Sensor, glucose, invasive
Applicant
Dexcom, Inc.
Date received
2022-10-14
Decision date
2023-01-12
Days to decision
90 days
Decision code
APPR
Product code
MDS
Advisory committee
Clinical Chemistry
Expedited review
No
Location
San Diego, CA
Statement
Approval to modify the prior inclusion criterion to the following: Clinical diagnosis of Type 1 or Type 2 diabetes with at least one (1) week of insulin initiation at time of study entry.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Stelo Glucose Biosensor System (K260935)Dexcom, Inc.2026-06-12
Dexcom G7 Continuous Glucose Monitoring System;Dexcom G7 15 Day Continuous Glucose Monitoring System (K261402)Dexcom, Inc.2026-06-08
Stelo Glucose Biosensor System (K261359)Dexcom, Inc.2026-05-21
Dexcom G7 Continuous Glucose Monitoring (CGM) System; Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System (K253737)Dexcom, Inc.2026-02-03
Dexcom G7 Continuous Glucose Monitoring (CGM) System, Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System (K253710)Dexcom, Inc.2025-12-17
Dexcom Smart Basal (K252818)Dexcom, Inc.2025-11-18
Dexcom G7 15 Day Continuous Glucose Monitoring System (K243214)Dexcom, Inc.2025-04-09
Dexcom G7 Continuous Glucose Monitoring System (K240902)Dexcom, Inc.2024-04-23